POM-V Prescription Required

Rispoval IBR-Marker Inactivated

Active ingredient: Infectious bovine rhinotraceitis virus

Form

Injection

Species

Cattle

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5141

What it's used for

For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to reduce the clinical signs and virus shedding and, in female cattle, t...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Infectious bovine rhinotrace...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Rispoval IBR-Marker Inactivated — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunisation of cattle against Infectious Bovine Rhinotracheitis (IBR), to
reduce the clinical signs and virus shedding and, in female cattle, to prevent
abortions associated with BoHV-1 infection. The vaccination of pregnant cattle will
prevent abortion associated with BoHV-1 infections as demonstrated during the
second trimester of gestation upon challenge 28 days after vaccination.

Revised: August 2024
AN: 02039/2023
Vaccinated cattle can be differentiated from field virus infected animals due to the
marker deletion, unless the cattle were previously vaccinated with a conventional
vaccine or infected with field virus.
Duration of immunity: 6 months.
Additional information on protection afforded by combined vaccination of
Rispoval IBR-Marker Vivum* with Rispoval IBR-Marker Inactivatum: for booster
immunisation after primary vaccination with Rispoval IBR-Marker Vivum* to reduce
the virus shedding and the clinical signs associated with BoHV-1 infection in cattle
and, in female cattle, to prevent abortions associated with BoHV-1 infection. This
vaccination of cattle will prevent abortion associated with BoHV-1 infections as
demonstrated during the third trimester of gestation upon challenge 86 days after the
booster vaccination.
Duration of immunity: 6 months after complete primary vaccination with Rispoval
IBR-Marker Vivum* followed by 12 months after annual booster with Rispoval IBR-
Marker Inactivatum.
In order to prevent abortion in female cattle that have received basic immunisation, a
single dose revaccination with Rispoval IBR-Marker Inactivatum is recommended to
be applied no later than by the start of the second trimester of each further
pregnancy.
* Where this veterinary medicinal product is authorised.

None.

Cattle:
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Injection site swelling
,
Allergic reaction
1
Transient subcutaneous, up to 5 cm, which subsides within 14 days.
Vaccinated animals should be observed for approximately 30 minutes following
immunisation. If such reactions occur, antiallergics should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or the national competent authority via
the national reporting system. See also section 16 of the package leaflet for contact
details.

Vaccinate healthy animals only.

Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

Revised: August 2024
AN: 02039/2023

Immunosuppressive substances, i.e. corticosteroids or Bovine Virus Diarrhoea
modified live vaccines, should be avoided in a period of 7 days prior to and after
vaccination as this may impair the development of the immunity.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store in a refrigerator (2 °C - 8 °C).
Do not freeze.
Protect from light.

Zero days.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Inactivated viral vaccine.
ATCvet code: QI02AA03
Glycoprotein gE is absent in virus particles of Rispoval IBR-Marker Inactivatum.
Therefore the vaccine virus, and the antibodies against it can be clearly differentiated
from field strains, or antibodies against the latter by serological methods, unless the
cattle were previously vaccinated with a conventional vaccine or infected with field
virus.
The vaccine induces immunity in cattle against clinical respiratory symptoms caused
by Bovine herpes virus. Following infection the intensity and duration of clinical
symptoms as well as the titre and duration of virus shedding are significantly
reduced. As with other vaccines, vaccination may not completely prevent but does
reduce risk of infection. The veterinary medicinal product induces antibodies in
vaccinated cattle, which are detected in the serum neutralisation test and in
conventional ELISA tests. With specific test kits these antibodies can be
differentiated - due to the lack of antibodies against gE - from those of field virus
infected animals or animals vaccinated with conventional vaccines.
Vaccination of all cattle in a herd, both infected and uninfected, is recommended.
Following use of Rispoval IBR-Marker Inactivatum the risk of infection, titre and
duration of virus shedding are all reduced. The duration of a programme to achieve
the status of a BoHV-1 free herd is dependent on the initial level of BoHV-1 infection
in the herd and the culling of remaining BoHV-1 positive animals.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.